Tonix Pharmaceuticals Holding Corp. (TNXP) is a Biotechnology company in the Healthcare sector, currently trading at $13.35. It has a SharesGrow Score of 49/100, indicating a mixed investment profile with 2 out of 7 criteria passed.
Valuation: TNXP trades at a trailing Price-to-Earnings (P/E) of -0.9 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.02.
Financials: revenue is $13M, +15.3%/yr average growth. Net income is $124M (loss), growing at -2.2%/yr. Net profit margin is -946.2% (negative). Gross margin is 49.3% (-39.6 pp trend).
Balance sheet: total debt is $1M against $245M equity (Debt-to-Equity (D/E) ratio 0.01, conservative). Current ratio is 7.42 (strong liquidity). Debt-to-assets is 0.5%. Total assets: $277M.
Analyst outlook: 6 / 7 analysts rate TNXP as buy (86%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 48/100 (Partial), Past 0/100 (Fail), Health 67/100 (Partial), Moat 28/100 (Fail), Future 90/100 (Pass), Income 10/100 (Fail).
